Tranilast

Identification

Name
Tranilast
Accession Number
DB07615
Type
Small Molecule
Groups
Approved, Investigational
Description

Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. It was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.

Structure
Thumb
Synonyms
  • N-(3,4-Dimethoxycinnamoyl)anthranilic acid
  • tranilast
  • tranilastum
External IDs
MK 341 / MK-341 / MK341
International/Other Brands
Rizaben
Categories
UNII
HVF50SMY6E
CAS number
53902-12-8
Weight
Average: 327.3313
Monoisotopic: 327.110672659
Chemical Formula
C18H17NO5
InChI Key
NZHGWWWHIYHZNX-CSKARUKUSA-N
InChI
InChI=1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+
IUPAC Name
2-[(2E)-3-(3,4-dimethoxyphenyl)prop-2-enamido]benzoic acid
SMILES
COC1=CC=C(\C=C\C(=O)NC2=CC=CC=C2C(O)=O)C=C1OC

Pharmacology

Indication

For the treatment of bronchial asthma, keloid and hypertrophic scar, and allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UHematopoietic prostaglandin D synthaseNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Tranilast is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Tranilast is combined with 19-norandrostenedione.Experimental, Illicit
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Tranilast.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Tranilast.Vet Approved
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Tranilast.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Tranilast.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Tranilast.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Tranilast.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Tranilast is combined with 5-androstenedione.Experimental, Illicit
AbciximabTranilast may increase the anticoagulant activities of Abciximab.Approved
AcebutololTranilast may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Tranilast.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Tranilast is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolTranilast may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Tranilast is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinTranilast may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Tranilast.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Tranilast is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Tranilast is combined with Aldosterone.Experimental, Investigational
AldoxorubicinTranilast may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Tranilast is combined with Alendronic acid.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Tranilast.Approved, Investigational
AliskirenTranilast may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Tranilast is combined with Alminoprofen.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Tranilast is combined with Aloxiprin.Experimental
AlprenololTranilast may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Tranilast.Approved, Investigational
AlteplaseTranilast may increase the anticoagulant activities of Alteplase.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Tranilast is combined with Amcinonide.Approved
AmikacinTranilast may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideTranilast may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Tranilast is combined with Aminosalicylic Acid.Approved
AmobarbitalThe metabolism of Tranilast can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Tranilast.Approved, Investigational
AmphetamineAmphetamine may decrease the sedative activities of Tranilast.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Tranilast.Approved, Investigational
AmrubicinTranilast may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AnagrelideTranilast may increase the anticoagulant activities of Anagrelide.Approved
AncrodTranilast may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Tranilast.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Tranilast is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Tranilast is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Tranilast is combined with anecortave acetate.Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Tranilast.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Tranilast is combined with Anisodamine.Investigational
AnistreplaseTranilast may increase the anticoagulant activities of Anistreplase.Approved
AnnamycinTranilast may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Tranilast.Approved
Antithrombin III humanTranilast may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Tranilast is combined with Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Tranilast is combined with Apocynin.Investigational
ApramycinTranilast may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Tranilast.Approved, Investigational
ArbekacinTranilast may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinTranilast may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanTranilast may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Tranilast.Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Tranilast.Approved
AstaxanthinTranilast may increase the anticoagulant activities of Astaxanthin.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Tranilast is combined with Atamestane.Investigational
AtenololTranilast may decrease the antihypertensive activities of Atenolol.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Tranilast is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Tranilast is combined with Atosiban.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tranilast.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tranilast.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tranilast.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Tranilast.Experimental
BalsalazideTranilast may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BarbexacloneThe metabolism of Tranilast can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Tranilast can be increased when combined with Barbital.Illicit
BatroxobinTranilast may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminTranilast may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Tranilast is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololTranilast may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinTranilast may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BemiparinTranilast may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Tranilast.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Tranilast is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Tranilast.Approved
BenorilateThe risk or severity of adverse effects can be increased when Tranilast is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Tranilast.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Tranilast.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Tranilast.Approved, Illicit
BenzydamineThe risk or severity of adverse effects can be increased when Tranilast is combined with Benzydamine.Approved
Benzylpenicilloyl PolylysineTranilast may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Tranilast.Investigational
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Tranilast.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Betamethasone.Approved, Vet Approved
BetaxololTranilast may decrease the antihypertensive activities of Betaxolol.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Tranilast.Approved, Investigational
BevantololTranilast may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Tranilast is combined with Bevonium.Experimental
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Tranilast.Approved, Investigational
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Tranilast.Approved, Investigational
BisoprololTranilast may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinTranilast may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololTranilast may decrease the antihypertensive activities of Bopindolol.Approved
Brefeldin AThe risk or severity of adverse effects can be increased when Brefeldin A is combined with Tranilast.Experimental
BrinaseTranilast may increase the anticoagulant activities of Brinase.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Tranilast.Approved
BucillamineThe risk or severity of adverse effects can be increased when Tranilast is combined with Bucillamine.Investigational
BucindololBucindolol may increase the hypotensive activities of Tranilast.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Tranilast is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Tranilast is combined with Bufexamac.Experimental
BuflomedilTranilast may increase the antiplatelet activities of Buflomedil.Experimental
BufuralolTranilast may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Bumadizone.Experimental
BumetanideTranilast may decrease the diuretic activities of Bumetanide.Approved
BunazosinBunazosin may increase the hypotensive activities of Tranilast.Investigational
BupranololTranilast may decrease the antihypertensive activities of Bupranolol.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Tranilast.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Tranilast.Approved
ButylphthalideTranilast may increase the antiplatelet activities of Butylphthalide.Investigational
Calcium AcetateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium Carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium Phosphate.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Tranilast.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Tranilast.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Tranilast.Withdrawn
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Tranilast.Experimental
CangrelorTranilast may increase the anticoagulant activities of Cangrelor.Approved
CaplacizumabTranilast may increase the anticoagulant activities of Caplacizumab.Investigational
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Tranilast.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Tranilast.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Tranilast is combined with Carbaspirin calcium.Experimental, Investigational
CarbomycinThe metabolism of Tranilast can be decreased when combined with Carbomycin.Vet Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Tranilast.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Tranilast.Approved, Vet Approved, Withdrawn
CarteololTranilast may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Tranilast.Approved, Investigational
CaseinThe therapeutic efficacy of Tranilast can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Tranilast.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Tranilast.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tranilast.Approved, Investigational
CeliprololTranilast may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CerivastatinThe risk or severity of adverse effects can be increased when Tranilast is combined with Cerivastatin.Withdrawn
CertoparinTranilast may increase the anticoagulant activities of Certoparin.Approved, Investigational
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Tranilast.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Tranilast.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tranilast.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Tranilast.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Tranilast.Illicit, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Tranilast.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Tranilast resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Tranilast.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Tranilast is combined with Ciclesonide.Approved, Investigational
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Tranilast.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tranilast.Approved
CilostazolTranilast may increase the anticoagulant activities of Cilostazol.Approved
CimetidineThe serum concentration of Tranilast can be increased when it is combined with Cimetidine.Approved
CinoxacinTranilast may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidTranilast may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Tranilast can be decreased when combined with Clarithromycin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Tranilast is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Tranilast is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Tranilast is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Tranilast is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Tranilast is combined with Clonixin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Tranilast.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Tranilast.Vet Approved
CloranololTranilast may decrease the antihypertensive activities of Cloranolol.Experimental
CloricromenTranilast may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneTranilast may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Tranilast.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Tranilast resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Tranilast resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Tranilast is combined with Collagenase clostridium histolyticum.Approved, Investigational
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Tranilast.Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Tranilast is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Tranilast is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Tranilast is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Tranilast is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Tranilast.Experimental
CyclosporineTranilast may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateTranilast may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinTranilast may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidTranilast may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Tranilast.Investigational
DarexabanTranilast may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Tranilast.Approved, Investigational
DaunorubicinTranilast may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Tranilast is combined with Deferasirox.Approved, Investigational
DefibrotideTranilast may increase the anticoagulant activities of Defibrotide.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Tranilast is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Tranilast.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Tranilast is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Tranilast is combined with Dersalazine.Investigational
DesirudinTranilast may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Tranilast is combined with Desmopressin.Approved
DesmoteplaseTranilast may increase the anticoagulant activities of Desmoteplase.Investigational
DesonideThe risk or severity of adverse effects can be increased when Tranilast is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Tranilast is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Tranilast is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Tranilast is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Tranilast.Approved, Investigational
DextranTranilast may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Tranilast may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Tranilast may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Tranilast may increase the anticoagulant activities of Dextran 75.Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Tranilast.Approved, Illicit
DibekacinTranilast may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Tranilast.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Tranilast.Approved, Vet Approved
DicoumarolTranilast may increase the anticoagulant activities of Dicoumarol.Approved
DiethylpropionDiethylpropion may decrease the sedative activities of Tranilast.Approved, Illicit
DifenpiramideThe risk or severity of adverse effects can be increased when Tranilast is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Tranilast is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Tranilast is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Tranilast is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Tranilast.Approved
DihydrostreptomycinTranilast may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Tranilast.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Tranilast.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Tranilast.Approved
DiphenadioneTranilast may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleTranilast may increase the anticoagulant activities of Dipyridamole.Approved
DitazoleTranilast may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DoxazosinDoxazosin may increase the hypotensive activities of Tranilast.Approved
DoxorubicinTranilast may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneTranilast may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaTranilast may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Tranilast is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Tranilast is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Tranilast is combined with E-6201.Investigational
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Tranilast.Approved
Edetic AcidTranilast may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanTranilast may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe serum concentration of Tranilast can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Tranilast.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Tranilast.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tranilast.Approved
EnoxacinTranilast may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinTranilast may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Tranilast.Experimental
EpanololTranilast may decrease the antihypertensive activities of Epanolol.Experimental
EpinastineEpinastine may increase the antiplatelet activities of Tranilast.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Tranilast is combined with Epirizole.Approved
EpirubicinTranilast may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneTranilast may decrease the antihypertensive activities of Eplerenone.Approved
EplivanserinTranilast may increase the anticoagulant activities of Eplivanserin.Investigational
eplivanserineTranilast may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tranilast.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Tranilast.Approved
EptifibatideTranilast may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Tranilast is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Tranilast is combined with Equilin.Approved
ErythromycinThe metabolism of Tranilast can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololTranilast may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Tranilast is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Tranilast is combined with Estrone sulfate.Approved
Etacrynic acidTranilast may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Tranilast.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Tranilast is combined with Ethenzamide.Experimental
Ethyl biscoumacetateTranilast may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Tranilast is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Tranilast.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Tranilast is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Tranilast.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Tranilast is combined with Evening primrose oil.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Tranilast.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Tranilast.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Tranilast is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Tranilast.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Tranilast.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Tranilast is combined with Fentiazac.Experimental
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Tranilast.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Feprazone.Experimental
Ferulic acidTranilast may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinTranilast may increase the anticoagulant activities of Fibrinolysin.Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Tranilast.Approved, Investigational
FleroxacinTranilast may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Tranilast.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluasterone.Investigational
FluconazoleThe serum concentration of Tranilast can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Tranilast.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Fludrocortisone.Approved
FluindioneTranilast may increase the anticoagulant activities of Fluindione.Investigational
FlumequineTranilast may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Tranilast is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Tranilast is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Tranilast is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Tranilast.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Tranilast is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tranilast.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluticasone propionate.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Tranilast.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Tranilast is combined with Fluvastatin.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Tranilast.Approved, Nutraceutical, Vet Approved
FondaparinuxTranilast may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumTranilast may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Tranilast.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Tranilast is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Tranilast.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Tranilast.Approved
FramycetinTranilast may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideTranilast may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateTranilast may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinTranilast may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinTranilast may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Tranilast.Approved, Withdrawn
GemifloxacinTranilast may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinTranilast may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinTranilast may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ATranilast may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GepefrineGepefrine may decrease the sedative activities of Tranilast.Experimental
GlucosamineGlucosamine may increase the antiplatelet activities of Tranilast.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Tranilast.Experimental
GPX-150Tranilast may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinTranilast may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Tranilast.Approved, Vet Approved
GuacetisalThe risk or severity of adverse effects can be increased when Tranilast is combined with Guacetisal.Experimental
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Tranilast.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Tranilast is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Tranilast is combined with Haloperidol.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Tranilast.Approved, Withdrawn
HE3286The risk or severity of adverse effects can be increased when Tranilast is combined with HE3286.Investigational
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Tranilast is combined with Hemoglobin crosfumaril.Experimental
HeparinTranilast may increase the anticoagulant activities of Heparin.Approved, Investigational
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Tranilast.Approved, Investigational
HexobarbitalThe metabolism of Tranilast can be increased when combined with Hexobarbital.Approved
HigenamineTranilast may increase the anticoagulant activities of Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Tranilast.Approved, Investigational
HydralazineTranilast may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Tranilast.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tranilast.Approved, Investigational
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Tranilast.Approved
HydroxytyrosolTranilast may increase the antiplatelet activities of Hydroxytyrosol.Investigational
Hygromycin BTranilast may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Tranilast is combined with Ibandronate.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Tranilast is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Tranilast.Approved
IbudilastIbudilast may increase the antiplatelet activities of Tranilast.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Tranilast.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Tranilast is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Tranilast.Approved
Icosapent ethylTranilast may increase the antiplatelet activities of Icosapent ethyl.Approved, Nutraceutical
IdarubicinTranilast may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxTranilast may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilTranilast may increase the antiplatelet activities of Ifenprodil.Approved, Investigational, Withdrawn
IfetrobanTranilast may increase the antiplatelet activities of Ifetroban.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tranilast.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Tranilast.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Tranilast is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Tranilast.Approved
IndenololTranilast may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenTranilast may increase the anticoagulant activities of Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Tranilast.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Tranilast is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Tranilast.Withdrawn
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Tranilast.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tranilast.Approved, Investigational
IsepamicinTranilast may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Tranilast.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Tranilast is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Tranilast is combined with Istaroxime.Investigational
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Tranilast.Approved, Investigational
JosamycinThe metabolism of Tranilast can be decreased when combined with Josamycin.Approved, Investigational
KanamycinTranilast may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Kebuzone.Experimental
KetanserinTranilast may increase the antiplatelet activities of Ketanserin.Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Tranilast.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Tranilast.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tranilast.Approved
KitasamycinThe metabolism of Tranilast can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Tranilast.Approved
LandiololTranilast may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Tranilast.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Tranilast.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Tranilast.Approved, Investigational
LepirudinTranilast may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanTranilast may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololTranilast may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinTranilast may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostLimaprost may increase the antiplatelet activities of Tranilast.Approved, Investigational
LinsidomineTranilast may increase the antiplatelet activities of Linsidomine.Experimental
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Tranilast.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Tranilast.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Tranilast is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Tranilast.Approved
LonazolacThe risk or severity of adverse effects can be increased when Tranilast is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Tranilast.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Tranilast.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Tranilast is combined with Loteprednol.Approved
LovastatinThe risk or severity of adverse effects can be increased when Tranilast is combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Tranilast is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Tranilast.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Tranilast.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Tranilast.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Tranilast.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Tranilast.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Tranilast is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Tranilast.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tranilast.Approved
MelagatranTranilast may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Tranilast is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Tranilast.Approved, Vet Approved
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Tranilast.Experimental
MephedroneMephedrone may decrease the sedative activities of Tranilast.Investigational
MephentermineMephentermine may decrease the sedative activities of Tranilast.Approved
MepindololTranilast may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Tranilast is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Tranilast.Investigational, Withdrawn
MethamphetamineMethamphetamine may decrease the sedative activities of Tranilast.Approved, Illicit
MethohexitalThe metabolism of Tranilast can be increased when combined with Methohexital.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Tranilast.Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Tranilast.Experimental
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Tranilast.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Tranilast is combined with Methyl salicylate.Approved, Vet Approved
MethylphenobarbitalThe metabolism of Tranilast can be increased when combined with Methylphenobarbital.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Tranilast is combined with Methylprednisolone.Approved, Vet Approved
MetipranololTranilast may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Tranilast.Approved
MetoprololTranilast may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideTranilast may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Tranilast.Experimental
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Tranilast.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Tranilast.Approved, Investigational, Vet Approved
MicronomicinTranilast may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidomafetamineMidomafetamine may decrease the sedative activities of Tranilast.Experimental, Illicit, Investigational
MilrinoneMilrinone may increase the antiplatelet activities of Tranilast.Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Tranilast.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Tranilast.Approved
MizoribineThe risk or severity of adverse effects can be increased when Tranilast is combined with Mizoribine.Investigational
MMDAMMDA may decrease the sedative activities of Tranilast.Experimental, Illicit
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Tranilast.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Mometasone.Approved, Vet Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Tranilast.Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Tranilast.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tranilast.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tranilast.Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Tranilast.Experimental
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Tranilast.Approved
NadololTranilast may decrease the antihypertensive activities of Nadolol.Approved
NadroparinTranilast may increase the anticoagulant activities of Nadroparin.Approved
NafamostatTranilast may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NafcillinThe metabolism of Tranilast can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Tranilast.Approved
NaftopidilTranilast may increase the antiplatelet activities of Naftopidil.Investigational
Nalidixic AcidTranilast may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Tranilast.Approved, Vet Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Tranilast.Approved
NCX 1022The risk or severity of adverse effects can be increased when Tranilast is combined with NCX 1022.Investigational
NeamineTranilast may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololTranilast may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinTranilast may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinTranilast may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Tranilast.Approved
NetilmicinTranilast may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Tranilast.Approved
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Tranilast.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Tranilast.Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tranilast.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Tranilast is combined with Nitroaspirin.Investigational
NitroprussideTranilast may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Tranilast.Approved
NorfloxacinTranilast may increase the neuroexcitatory activities of Norfloxacin.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Tranilast.Approved, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Tranilast is combined with Obinutuzumab.Approved
OleandomycinThe metabolism of Tranilast can be decreased when combined with Oleandomycin.Vet Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Tranilast is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Tranilast.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tranilast.Approved
OlsalazineTranilast may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of can be d when Tranilast is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Tranilast.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Tranilast.Approved, Nutraceutical
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Tranilast.Experimental
OrgoteinThe risk or severity of adverse effects can be increased when Tranilast is combined with Orgotein.Vet Approved
OtamixabanTranilast may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tranilast.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Tranilast.Approved
Oxolinic acidTranilast may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololTranilast may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Tranilast.Approved, Withdrawn
OzagrelTranilast may increase the anticoagulant activities of Ozagrel.Investigational
PafuramidineThe risk or severity of adverse effects can be increased when Pafuramidine is combined with Tranilast.Investigational
PamidronateThe risk or severity of adverse effects can be increased when Tranilast is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Tranilast is combined with Parecoxib.Approved
ParnaparinTranilast may increase the anticoagulant activities of Parnaparin.Approved, Investigational
ParomomycinTranilast may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Tranilast is combined with Parthenolide.Investigational
PazufloxacinTranilast may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinTranilast may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololTranilast may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateTranilast may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Tranilast.Approved
PentobarbitalThe metabolism of Tranilast can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Tranilast.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Tranilast.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Tranilast.Approved
PhenindioneTranilast may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Tranilast can be increased when combined with Phenobarbital.Approved
PhenprocoumonTranilast may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenterminePhentermine may decrease the sedative activities of Tranilast.Approved, Illicit
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Tranilast.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Tranilast.Approved, Vet Approved
PicotamideTranilast may increase the anticoagulant activities of Picotamide.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Tranilast.Approved, Investigational
PindololTranilast may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidTranilast may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinTranilast may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideTranilast may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Tranilast.Approved, Investigational
Piromidic acidTranilast may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Tranilast.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Tranilast is combined with Pirprofen.Experimental
PitavastatinThe risk or severity of adverse effects can be increased when Tranilast is combined with Pitavastatin.Approved
Platelet Activating FactorTranilast may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinTranilast may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinTranilast may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Tranilast.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Tranilast.Approved, Investigational, Vet Approved
PractololTranilast may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Tranilast.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Tranilast is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Tranilast is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Tranilast is combined with Prasterone sulfate.Investigational
PrasugrelTranilast may increase the anticoagulant activities of Prasugrel.Approved
PravastatinThe risk or severity of adverse effects can be increased when Tranilast is combined with Pravastatin.Approved
PrazosinPrazosin may increase the hypotensive activities of Tranilast.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Tranilast is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Tranilast is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Tranilast is combined with Pregnenolone.Experimental, Investigational
PrimidoneThe metabolism of Tranilast can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Tranilast can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Tranilast is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Tranilast is combined with Propacetamol.Approved, Investigational
PropranololTranilast may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Tranilast.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Tranilast.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Tranilast.Vet Approved
Protein CTranilast may increase the anticoagulant activities of Protein C.Approved
Protein S humanTranilast may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeTranilast may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinTranilast may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Tranilast.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Tranilast.Investigational
PuromycinTranilast may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Tranilast.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Tranilast.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Tranilast.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Tranilast.Experimental
RamatrobanTranilast may increase the antiplatelet activities of Ramatroban.Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Tranilast.Approved
RelcovaptanTranilast may increase the antiplatelet activities of Relcovaptan.Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Tranilast.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Tranilast.Approved, Experimental, Investigational
ReteplaseTranilast may increase the anticoagulant activities of Reteplase.Approved
ReviparinTranilast may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinTranilast may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RidogrelRidogrel may increase the antiplatelet activities of Tranilast.Approved
RifabutinThe serum concentration of Tranilast can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Tranilast can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Tranilast can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Tranilast can be decreased when it is combined with Rifaximin.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Tranilast is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Tranilast is combined with Risedronate.Approved, Investigational
RitobegronRitobegron may decrease the sedative activities of Tranilast.Investigational
RivaroxabanTranilast may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Tranilast.Investigational, Withdrawn
RosiglitazoneTranilast may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
RosoxacinTranilast may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RosuvastatinThe risk or severity of adverse effects can be increased when Tranilast is combined with Rosuvastatin.Approved
RufloxacinTranilast may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinTranilast may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Tranilast.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Tranilast is combined with Salicylamide.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Tranilast.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Tranilast.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Tranilast.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Tranilast.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Tranilast.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Tranilast.Approved
SarpogrelateTranilast may increase the anticoagulant activities of Sarpogrelate.Investigational
SaruplaseTranilast may increase the anticoagulant activities of Saruplase.Experimental
SecobarbitalThe metabolism of Tranilast can be increased when combined with Secobarbital.Approved, Vet Approved
SelexipagTranilast may increase the anticoagulant activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Tranilast is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Tranilast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Tranilast is combined with Serrapeptase.Investigational
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Tranilast.Approved
SevofluraneSevoflurane may increase the antiplatelet activities of Tranilast.Approved, Vet Approved
SilodosinSilodosin may increase the hypotensive activities of Tranilast.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Tranilast is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Tranilast.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Tranilast.Approved, Investigational
SisomicinTranilast may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinTranilast may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Tranilast.Approved
SolithromycinThe metabolism of Tranilast can be decreased when combined with Solithromycin.Investigational
SotalolTranilast may decrease the antihypertensive activities of Sotalol.Approved
SP1049CTranilast may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinTranilast may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinTranilast may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Tranilast.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Tranilast.Investigational
StreptokinaseTranilast may increase the anticoagulant activities of Streptokinase.Approved, Investigational
StreptomycinTranilast may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinTranilast may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Tranilast.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tranilast.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Tranilast.Approved
SulodexideTranilast may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Tranilast.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Tranilast.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Suxibuzone.Experimental
TacrolimusTranilast may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Tranilast.Approved
TalinololTranilast may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Tranilast.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Tranilast.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Tranilast.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Tranilast.Approved
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Tranilast.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Tranilast is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Tranilast is combined with Technetium Tc-99m medronate.Approved
TelithromycinThe metabolism of Tranilast can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Tranilast.Approved, Investigational
TemafloxacinTranilast may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Tranilast.Experimental, Investigational
TenecteplaseTranilast may increase the anticoagulant activities of Tenecteplase.Approved
TenidapThe risk or severity of adverse effects can be increased when Tranilast is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Tranilast is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Tranilast.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tranilast is combined with Tepoxalin.Vet Approved
TerazosinTerazosin may increase the hypotensive activities of Tranilast.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Tranilast.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Tranilast.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Tranilast is combined with Teriflunomide.Approved
TertatololTranilast may decrease the antihypertensive activities of Tertatolol.Experimental
TesmilifeneTesmilifene may increase the antiplatelet activities of Tranilast.Investigational
ThiamylalThe metabolism of Tranilast can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Tranilast can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Tranilast.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Tranilast.Approved
TicagrelorTranilast may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineTranilast may increase the anticoagulant activities of Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Tranilast is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololTranilast may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tranilast is combined with Tinoridine.Investigational
TinzaparinTranilast may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolTranilast may increase the anticoagulant activities of Tioclomarol.Experimental
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Tranilast.Approved
TipranavirTipranavir may increase the antiplatelet activities of Tranilast.Approved, Investigational
TirofibanTranilast may increase the anticoagulant activities of Tirofiban.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tranilast is combined with Tixocortol.Approved, Withdrawn
TobramycinTranilast may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Tranilast.Experimental
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tranilast is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Tranilast.Approved
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Tranilast.Approved, Vet Approved
TorasemideTranilast may decrease the diuretic activities of Torasemide.Approved
TositumomabThe risk or severity of adverse effects can be increased when Tranilast is combined with Tositumomab.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Tranilast.Approved
TrapidilTranilast may increase the antiplatelet activities of Trapidil.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Tranilast.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Tranilast.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Tranilast is combined with Triamcinolone.Approved, Vet Approved
TriamtereneTranilast may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tranilast is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Tranilast.Approved, Vet Approved
TriflusalTranilast may increase the anticoagulant activities of Triflusal.Approved, Investigational
TrimazosinTrimazosin may increase the hypotensive activities of Tranilast.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Tranilast.Approved, Investigational
TriptolideThe risk or severity of adverse effects can be increased when Tranilast is combined with Triptolide.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Tranilast is combined with Trolamine salicylate.Approved
TrovafloxacinTranilast may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinTranilast may increase the anticoagulant activities of Troxerutin.Investigational
TylosinThe metabolism of Tranilast can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Tranilast is combined with Ubidecarenone.Approved, Investigational, Nutraceutical
UlobetasolThe risk or severity of adverse effects can be increased when Tranilast is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Tranilast.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Tranilast.Investigational
UrokinaseTranilast may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Tranilast.Investigational, Withdrawn
ValrubicinTranilast may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Tranilast.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Tranilast.Approved
Vitamin EVitamin E may increase the antiplatelet activities of Tranilast.Approved, Nutraceutical, Vet Approved
VorapaxarTranilast may increase the anticoagulant activities of Vorapaxar.Approved
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Tranilast.Approved, Investigational
WarfarinThe risk or severity of adverse effects can be increased when Tranilast is combined with Warfarin.Approved
XimelagatranTranilast may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Tranilast.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Tranilast.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Tranilast.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Tranilast is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Tranilast.Withdrawn
Zoptarelin doxorubicinTranilast may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinTranilast may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D02027
PubChem Compound
5282230
PubChem Substance
99444086
ChemSpider
4445411
BindingDB
21613
ChEBI
77572
ChEMBL
CHEMBL415324
HET
D27
Wikipedia
Tranilast
PDB Entries
2vd0

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1WithdrawnTreatmentRheumatoid Arthritis1
2CompletedTreatmentActive Rheumatoid Arthritis1
2CompletedTreatmentGout Acute / Hyperuricemia2
3CompletedTreatmentPterygium1
4CompletedTreatmentConjunctivitis, Seasonal Allergic1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0084 mg/mLALOGPS
logP2.89ALOGPS
logP3.56ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)3.55ChemAxon
pKa (Strongest Basic)-2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area84.86 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity91.52 m3·mol-1ChemAxon
Polarizability34.2 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5905
Blood Brain Barrier-0.58
Caco-2 permeable+0.5
P-glycoprotein substrateNon-substrate0.6922
P-glycoprotein inhibitor INon-inhibitor0.7716
P-glycoprotein inhibitor IINon-inhibitor0.5842
Renal organic cation transporterNon-inhibitor0.9433
CYP450 2C9 substrateNon-substrate0.6853
CYP450 2D6 substrateNon-substrate0.8054
CYP450 3A4 substrateSubstrate0.5548
CYP450 1A2 substrateNon-inhibitor0.9137
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9451
CYP450 2C19 inhibitorNon-inhibitor0.9167
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7384
Ames testNon AMES toxic0.6665
CarcinogenicityNon-carcinogens0.871
BiodegradationNot ready biodegradable0.8218
Rat acute toxicity2.4428 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9921
hERG inhibition (predictor II)Non-inhibitor0.8008
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-1900000000-7541d25405a74d897cf6
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-2900000000-d54b9ceefe589f6ddc0b

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-cinnamoylanthranilic acids. These are aromatic compounds containing a cinnamic acid conjugated to an anthranilic acid.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Cinnamic acids and derivatives
Sub Class
Cinnamic acid amides
Direct Parent
N-cinnamoylanthranilic acids
Alternative Parents
Acylaminobenzoic acid and derivatives / Dimethoxybenzenes / Anilides / Benzoic acids / Styrenes / Phenoxy compounds / N-arylamides / Anisoles / Benzoyl derivatives / Alkyl aryl ethers
show 8 more
Substituents
N-cinnamoylanthranilic acid / Acylaminobenzoic acid or derivatives / O-dimethoxybenzene / Dimethoxybenzene / Benzoic acid or derivatives / Benzoic acid / Anilide / Phenoxy compound / Anisole / Phenol ether
show 23 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
dimethoxybenzene, cinnamamides, amidobenzoic acid (CHEBI:77572)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Protein homodimerization activity
Specific Function
Bifunctional enzyme which catalyzes both the conversion of PGH2 to PGD2, a prostaglandin involved in smooth muscle contraction/relaxation and a potent inhibitor of platelet aggregation, and the con...
Gene Name
HPGDS
Uniprot ID
O60760
Uniprot Name
Hematopoietic prostaglandin D synthase
Molecular Weight
23343.65 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on September 15, 2010 15:24 / Updated on December 01, 2017 15:53